Development
SpringWorks Therapeutics, Inc.
SWTX
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 28.55% | -0.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.70% | 1.38% | |||
| Operating Income | -17.22% | -1.38% | |||
| Income Before Tax | -18.74% | -1.94% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -18.74% | -1.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.74% | -1.94% | |||
| EBIT | -17.22% | -1.38% | |||
| EBITDA | -17.27% | -1.26% | |||
| EPS Basic | -13.62% | -1.84% | |||
| Normalized Basic EPS | -13.63% | -1.85% | |||
| EPS Diluted | -13.62% | -1.84% | |||
| Normalized Diluted EPS | -13.63% | -1.85% | |||
| Average Basic Shares Outstanding | 4.50% | 0.09% | |||
| Average Diluted Shares Outstanding | 4.50% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||